Phase 2 N=34 Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 5.5 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=119 Naproxen for Pain Control With Intrauterine Device Insertion
Contraception
Primary: Pain at Time of IUD Insertion Using a 10 cm (100 mm) Visual Analog Scale (VAS) — 69; 66 units on a scale
Phase 1 N=12 Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection)
Rett Syndrome
Primary: Adverse Events — 4; 4; 2; 17 Adverse events
N/A N=30 Evaluate Patients With Chronic Hepatitis by Three-dimensional Force-controlled Ultrasound Measurement
Fatty Liver
Primary: Subcutaneous Fat in Steatosis Patients — 9.54; 10.48; 5.24; 4.09 cm^3
Phase 4 N=212 Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants Preferring the Inhaler Based on the Number of Steps Needed to Take the COPD Medication — 73; 20; 7 Percentage of participants — p=<0.001
N/A N=86 Pregabalin for the Treatment of Pain After Posterior Spinal Fusions
Lumbar Spinal Fusions
Primary: Patient Controlled Analgesia (PCA) Hydromorphone Usage — 44; 39 mL
Phase 2 N=13 Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Relapse Multiple Myeloma · Refractory Multiple Myeloma
Primary: Safety and Efficacy of High Dose Carfilzomib — 3; 13 Participants
Phase 2 N=527 A Study of LY3015014 in Participants With High Cholesterol
Hypercholesterolemia
Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) — 7.6; -14.9; -40.5; -50.5 Percentage change
Phase 2 N=222 A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Carcinoma, Non-Small-Cell Lung
Primary: Confirmed Objective Response Rate (ORR) as Assessed by Investigator — 45.5; 57.3 percentage of participants
Phase 3 N=309 A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
Hypercholesterolemia
Primary: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -19.3; -44.0; -49.1; -55.6 Percentage Change — p=<0.001
Phase 2 N=137 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Lymphoma, Large-Cell, Anaplastic · Carcinoma, Non-Small-Cell Lung
Primary: Recommended Phase 2 Dose (RP2D) of Brigatinib — NA mg
Phase 2 N=73 Effectiveness of Modafinil and D-amphetamine in Treating Cocaine Dependent Individuals
Cocaine-Related Disorders
Primary: Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment — 9.25; 6.09; 6; 4.91 number of…
Phase 1 N=6 A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.
Advanced Solid Tumors · Lymphomas
Primary: Maximum Plasma Concentration (Cmax) of Radiolabeled 14^C-Lenvatinib and Non-Radiolabeled Lenvatinib — 485.2; 426.8 ng/mL
Phase 2 N=58 Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
Uveitis
Primary: Percentage of Participants With at Least 2-step Reduction in Vitreous Haze (VH) or Prednisone Dose <10 mg/Day at Week 16 — 30.0; 46.1 Percentage of participants — p=0.2354
Phase 1 N=54 A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.
Schizophrenia
Primary: Physical Examination Shift Table — 1; 1; 0; 0 Participants abnormal at end of study